<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> chagasic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> affects 20% of <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas' disease</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>At present, <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas' disease</z:e> chemotherapy uses <z:chebi fb="0" ids="34890">nitrofurans</z:chebi>, benznidazole (Rochagan®, Rodanil®, Roche) or nifurtimox (Lampit®, Bayer) </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment during <z:hpo ids='HP_0011009'>acute</z:hpo> and recent <z:hpo ids='HP_0011010'>chronic</z:hpo> phases in childhood effects 71.5% and 57.6%, respectively, of parasitological cure </plain></SENT>
<SENT sid="3" pm="."><plain>However, in clinical trials during the late <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, only 5.9% of parasitological cure were achieved </plain></SENT>
<SENT sid="4" pm="."><plain>This review focuses on the benefit from aetiological treatment to avoid, stop or revert <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Divergent data gathered from clinical practice are not convincing to support prescription of aetiological treatment as routine for indeterminate and cardiac <z:hpo ids='HP_0011010'>chronic</z:hpo> patients </plain></SENT>
</text></document>